Cargando…

Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model

Colistin is a drug of last resort to treat extreme drug-resistant Enterobacterales, but is limited by dose-dependent toxicity and the emergence of resistance. A recently developed antimicrobial pseudopeptide, Pep16, which acts on the cell membrane, may be synergistic with colistin and limit the emer...

Descripción completa

Detalles Bibliográficos
Autores principales: Chosidow, Samuel, Fantin, Bruno, Nicolas, Irène, Mascary, Jean-Baptiste, Chau, Françoise, Bordeau, Valérie, Verdier, Marie-Clemence, Rocheteau, Pierre, Guérin, Francois, Cattoir, Vincent, de Lastours, Victoire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854584/
https://www.ncbi.nlm.nih.gov/pubmed/36671282
http://dx.doi.org/10.3390/antibiotics12010081
_version_ 1784873157071470592
author Chosidow, Samuel
Fantin, Bruno
Nicolas, Irène
Mascary, Jean-Baptiste
Chau, Françoise
Bordeau, Valérie
Verdier, Marie-Clemence
Rocheteau, Pierre
Guérin, Francois
Cattoir, Vincent
de Lastours, Victoire
author_facet Chosidow, Samuel
Fantin, Bruno
Nicolas, Irène
Mascary, Jean-Baptiste
Chau, Françoise
Bordeau, Valérie
Verdier, Marie-Clemence
Rocheteau, Pierre
Guérin, Francois
Cattoir, Vincent
de Lastours, Victoire
author_sort Chosidow, Samuel
collection PubMed
description Colistin is a drug of last resort to treat extreme drug-resistant Enterobacterales, but is limited by dose-dependent toxicity and the emergence of resistance. A recently developed antimicrobial pseudopeptide, Pep16, which acts on the cell membrane, may be synergistic with colistin and limit the emergence of resistance. We investigated Pep16 activity against Escherichia coli with varying susceptibility to colistin, in vitro and in a murine peritonitis model. Two isogenic derivatives of E. coli CFT073 (susceptible and resistant to colistin) and 2 clinical isolates (susceptible (B119) and resistant to colistin (Af31)) were used. Pep16 activity, alone and in combination with colistin, was determined in vitro (checkerboard experiments, time–kill curves, and flow cytometry to investigate membrane permeability). Toxicity and pharmacokinetic analyses of subcutaneous Pep16 were performed in mice, followed by the investigation of 10 mg/kg Pep16 + 10 mg/kg colistin (mimicking human concentrations) in a murine peritonitis model. Pep16 alone was inactive (MICs = 32–64 mg/L; no bactericidal effect). A concentration-dependent bactericidal synergy of Pep16 with colistin was evidenced on all strains, confirmed by flow cytometry. In vivo, Pep16 alone was ineffective. When Pep16 and colistin were combined, a significant decrease in bacterial counts in the spleen was evidenced, and the combination prevented the emergence of colistin-resistant mutants, compared to colistin alone. Pep16 synergizes with colistin in vitro, and the combination is more effective than colistin alone in a murine peritonitis by reducing bacterial counts and the emergence of resistance. Pep16 may optimize colistin use, by decreasing the doses needed, while limiting the emergence of colistin-resistant mutants.
format Online
Article
Text
id pubmed-9854584
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98545842023-01-21 Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model Chosidow, Samuel Fantin, Bruno Nicolas, Irène Mascary, Jean-Baptiste Chau, Françoise Bordeau, Valérie Verdier, Marie-Clemence Rocheteau, Pierre Guérin, Francois Cattoir, Vincent de Lastours, Victoire Antibiotics (Basel) Article Colistin is a drug of last resort to treat extreme drug-resistant Enterobacterales, but is limited by dose-dependent toxicity and the emergence of resistance. A recently developed antimicrobial pseudopeptide, Pep16, which acts on the cell membrane, may be synergistic with colistin and limit the emergence of resistance. We investigated Pep16 activity against Escherichia coli with varying susceptibility to colistin, in vitro and in a murine peritonitis model. Two isogenic derivatives of E. coli CFT073 (susceptible and resistant to colistin) and 2 clinical isolates (susceptible (B119) and resistant to colistin (Af31)) were used. Pep16 activity, alone and in combination with colistin, was determined in vitro (checkerboard experiments, time–kill curves, and flow cytometry to investigate membrane permeability). Toxicity and pharmacokinetic analyses of subcutaneous Pep16 were performed in mice, followed by the investigation of 10 mg/kg Pep16 + 10 mg/kg colistin (mimicking human concentrations) in a murine peritonitis model. Pep16 alone was inactive (MICs = 32–64 mg/L; no bactericidal effect). A concentration-dependent bactericidal synergy of Pep16 with colistin was evidenced on all strains, confirmed by flow cytometry. In vivo, Pep16 alone was ineffective. When Pep16 and colistin were combined, a significant decrease in bacterial counts in the spleen was evidenced, and the combination prevented the emergence of colistin-resistant mutants, compared to colistin alone. Pep16 synergizes with colistin in vitro, and the combination is more effective than colistin alone in a murine peritonitis by reducing bacterial counts and the emergence of resistance. Pep16 may optimize colistin use, by decreasing the doses needed, while limiting the emergence of colistin-resistant mutants. MDPI 2023-01-03 /pmc/articles/PMC9854584/ /pubmed/36671282 http://dx.doi.org/10.3390/antibiotics12010081 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chosidow, Samuel
Fantin, Bruno
Nicolas, Irène
Mascary, Jean-Baptiste
Chau, Françoise
Bordeau, Valérie
Verdier, Marie-Clemence
Rocheteau, Pierre
Guérin, Francois
Cattoir, Vincent
de Lastours, Victoire
Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model
title Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model
title_full Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model
title_fullStr Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model
title_full_unstemmed Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model
title_short Synergistic Activity of Pep16, a Promising New Antibacterial Pseudopeptide against Multidrug-Resistant Organisms, in Combination with Colistin against Multidrug-Resistant Escherichia coli, In Vitro and in a Murine Peritonitis Model
title_sort synergistic activity of pep16, a promising new antibacterial pseudopeptide against multidrug-resistant organisms, in combination with colistin against multidrug-resistant escherichia coli, in vitro and in a murine peritonitis model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854584/
https://www.ncbi.nlm.nih.gov/pubmed/36671282
http://dx.doi.org/10.3390/antibiotics12010081
work_keys_str_mv AT chosidowsamuel synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT fantinbruno synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT nicolasirene synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT mascaryjeanbaptiste synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT chaufrancoise synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT bordeauvalerie synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT verdiermarieclemence synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT rocheteaupierre synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT guerinfrancois synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT cattoirvincent synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel
AT delastoursvictoire synergisticactivityofpep16apromisingnewantibacterialpseudopeptideagainstmultidrugresistantorganismsincombinationwithcolistinagainstmultidrugresistantescherichiacoliinvitroandinamurineperitonitismodel